Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 314

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 314
---
 Common Warrants and a trading market is not expected to develop. Rights as a Stockholder.Except as otherwise provided in the February 2025 Common Warrants or by virtue of a holder’s ownership of shares of our Common Stock, the holders of the February 2025 Common Warrants do not have the rights or privileges of holders of our Common Stock, including any voting rights, unless and until they exercise their February 2025 Common Warrants. 184 Amendments.The February 2025 Common Warrants may be amended with the written consent of the holder of such February 2025 Common Warrant and us. Listing.There is no established public trading market for the February 2025 Common Warrants, and we do not expect a market to develop. In addition, we do not intend to apply for listing of the February 2025 Common Warrants on any national securities exchange. Anti-Takeover Provisions Section 203 of the Delaware General Corporation Law We are subject to Section 203 of the DGCL, which generally prohibits a publicly held Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:

| ● | before such date, the board                                                                                                           
 of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming 
 an interested stockholder;                                                                                                            |

| ● | upon completion of the transaction                                                                                                     
 that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock 
 of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding,  
 but not the outstanding voting stock owned by the interested stockholder, those shares owned (1) by persons who are directors and also 
 officers and (2) employee stock plans in which employee participants do not have the right to determine confidentially whether shares  
 held subject to the plan will be tendered in a tender or exchange offer; or                                                            |

| ● | on or after such date, the                                                                                                                       
 business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not           
 by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. |

In general, Section 203 defines a “business combination” to include the following:

| ● | any